Join Dr. Chris Favilla as he discusses non-invasive measurement of cerebral blood flow and potential applications.

Cerebral blood flow optimization is a pillar of clinical management of various neurological conditions. However, continuous non-invasive cerebral hemodynamic monitoring presents a significant challenge even in the most advanced health care settings. Here, we will discuss how biomedical optical imaging modalities are well positioned to address this unmet need. Recent studies will be leveraged to support the idea that optically-derived cerebral blood flow can (1) serve as a surrogate endpoint for early-phase trials aimed at hemodynamic optimization, (2) be used to quantify microvascular reperfusion in stroke, (3) detect large vessel occlusion, and (4) monitor patients at risk of hemodynamic failure. The overarching goal is to highlight the diversity of potential clinical applications to inspire cutting edge research that will ultimately improve the care we provide to patients with cerebrovascular disease.

Key Topics Include:

  • After endovascular therapy for large vessel occlusion stroke, bedside optical imaging can differentiate microvascular reperfusion
  • High temporal resolution of optical imaging allows for characterization of the CBF waveform, which reveals a multitude of future clinical applications
  • Optical CBF imaging can identify large vessel occlusions among patients with suspected stroke and therefore holds promise as a prehospital stroke care (i.e., patient triage and routing to appropriate stroke centers)

Presenters

Chris Favilla, ;MD

Chris Favilla, MD

Associate Professor/Director
Neurology/Non-invasive Cerebral Hemodynamic Evaluation (NICHE) Center
University of Pennsylvania

Dr. Chris Favilla, MD is an Associate Professor of Neurology and Director of the Non-invasive Cerebral Hemodynamic Evaluation (NICHE) Center at the University of Pennsylvania; his lab is dedicated to improving acute stroke care by leveraging these innovative bedside techniques to develop novel stroke therapies aimed at optimizing cerebral hemodynamics.
Watch Webinar

Production Partner

Openwater

Openwater was founded in 2016 to explore an idea: What if advancements in fields as diverse as consumer electronics, semiconductor device physics, and artificial intelligence could come together for a future where the profound act of curing disease becomes a reality for all, transcending borders and transforming the course of human health. ​The world of healthcare diagnostics and therapeutics could be transformed the way that semiconductors and software have transformed everything else. This is no dream: 7 years into the journey of starting Openwater we now have strong clinical feasibility data that could lead to products which diagnose and treat a spectrum of diseases, from aggressive cancers to mental health disorders and debilitating strokes and beyond touching on treatments for COVID/long COVID, stimulating stem cells, and rejuvenation of senescent cells.

VIEW PROFILE
Openwater

Additional Content From Openwater

Transcranial Focused Ultrasound Neuromodulation of the Default Mode Network in the Treatment of Depression and Promotion of Wellness

Transcranial Focused Ultrasound Neuromodulation of the Default Mode Network in the Treatment of Depression and Promotion of Wellness

In this webinar, Dr. John Allen will introduce how low-intensity transcranial focused ultrasound (litFUS), a non-invasive, high-precision neuromodulation technique, has the potential to modulate Default Mode Network (DMN) activity. Emerging evidence suggests that litFUS may reduce Repetitive Negative Thinking (RNT) and mood-related symptoms in clinical populations, and also promote emotional wellness in nonclinical groups.

Related Content